Lead Sponsor

Tanabe Pharma Corporation

Age

20 - 75 years

Sex

ALL

Healthy Volunteers

No

•Patients who are defined as "definite ALS," "probable ALS" or "probable-laboratory-supported ALS," met diagnostic criteria revised EL Escorial for Airlie House.
•Patients who cannot take at least one action of eating a meal, excreting, or moving with oneself alone, and need assistance in everyday life.
•Patients whose progress of the condition during 12 weeks before administration meet other requirements.

•Patients judged to be inadequate to participate in this study by their physician, because those patients' general condition deteriorated to the point that they need to be hospitalized for severe hepatic disease, sever heart disease, sever renal disease and so on, or they need to be administered antibiotics to infection.
•Patients who complain the difficulty in breathing caused by deteriorating the respiratory function.
•Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone.
•Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception.
•Patients who have been administered other investigational products within 12 weeks before consent, or who are participating in other clinical trials at present.

Related studies

NCT03233646 · Alzheimer's Disease, Mild Cognitive Impairment, and more

NCT07233148 · Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND), and more

NCT07187388 · Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), and more

NCT07202494 · Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, and more

NCT04244630 · Amyotrophic Lateral Sclerosis (ALS)

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III